Misidentifications are a common phenomenon in unfamiliar face processing, but little is known about the underlying cognitive and neural mechanisms. We used the face identity-sensitive N250r component of the event-related brain potential as a measure of identity-sensitive face matching process in visual working memory. Two face images were presented in rapid succession, and participants had to judge whether they showed the same or two different individuals. Identity match and mismatch trials were presented in random sequence. On similar mismatch trials, perceptually similar faces of two different individuals were shown, while two physically distinct faces were presented on dissimilar mismatch trials. Misidentification errors occurred on 40% of all similar mismatch trials. N250r components were elicited not only in response to an identity match, but also on trials with misidentification errors. This misidentification N250r was smaller and emerged later than the N250r to correctly detected identity repetitions. Importantly, N250r components were entirely eliminated on similar mismatch trials where participants correctly reported two different facial identities. Results show that misidentification errors are not primarily a post-perceptual decision-related phenomenon, but are generated during early visual stages of identity-related face processing. Misidentification errors occur when stored representations of a particular individual face in visual working memory are incorrectly activated by a perceptual match with a different face.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.neuropsychologia.2015.09.021 | DOI Listing |
Elife
January 2025
Integrative Model-Based Cognitive Neuroscience Research Unit, University of Amsterdam, Amsterdam, Netherlands.
This study investigates the functional network underlying response inhibition in the human brain, particularly the role of the basal ganglia in successful action cancellation. Functional magnetic resonance imaging (fMRI) approaches have frequently used the stop-signal task to examine this network. We merge five such datasets, using a novel aggregatory method allowing the unification of raw fMRI data across sites.
View Article and Find Full Text PDFInt J Cardiol Heart Vasc
February 2025
Faculty of Medicine, Tanta University, Tanta, Egypt.
Background: Aortic stenosis (AS) remains a prevalent and serious global health concern, exacerbated by an aging population worldwide. This valvular disease, when symptomatic and without appropriate intervention, severe AS can drastically reduce life expectancy. In our systematic review and -analysis, we aim to synthesize available evidence to guide clinical decision-making by comparing the performance of TAVR and SAVR, specifically in patients with severe AS and a small aortic annulus.
View Article and Find Full Text PDFInt J Colorectal Dis
January 2025
Internal Medicine, Jilin Cancer Hospital, Changchun, China.
Purpose: This phase II study is designed to evaluate the combination therapy involving suvemcitug and envafolimab with FOLFIRI in microsatellite-stable or mismatch repair-proficient (MSS/pMMR) colorectal cancer (CRC) in the second-line treatment setting.
Methods: This study is a non-randomized, open-label prospective study comprising multiple cohorts (NCT05148195). Here, we only report the data from the CRC cohort.
Expert Rev Vaccines
January 2025
Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd, Beijing, China.
Background: The development of bivalent or multivalent vaccines offers a promising strategy for combating SARS-CoV-2 mutations.
Research Design And Methods: In this phase 2 trial, conducted from 1 December 2021, to 25 July 2023, 392 unvaccinated adults aged ≥18 years were randomized to receive a primary series of two doses and a booster dose of SCTV01C, a bivalent protein SARS-CoV-2 vaccine.
Results: Geometric mean titers (GMTs) of neutralizing antibodies (nAb) against live Alpha, Beta, Delta, and Omicron showed 85.
Sci Rep
January 2025
Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China.
This study evaluates the cost-effectiveness of adding durvalumab to chemotherapy, with subsequent maintenance either with olaparib (DOCT) or without olaparib (DCT), versus chemotherapy alone (CT) as a first-line treatment for advanced endometrial cancer (EC) in the United States, stratified by mismatch repair deficiency (dMMR) and proficiency (pMMR). A Markov model based on DUO-E Phase III trial data simulated disease progression and outcomes. Total costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICER) were evaluated.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!